Allergenic vaccines administration and inhibitor development in haemophilia.
N
N
Bermejo
C
C
Martín Aguilera
F
F
Carnicero
J
J
Bergua
D000293:Adolescent; D000485:Allergens / Q000008:administration & dosage / Q000276:immunology; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D019774:Blood Coagulation Factor Inhibitors / Q000097:blood / Q000276:immunology*; D003888:Desensitization, Immunologic / Q000009:adverse effects; D005169:Factor VIII / Q000008:administration & dosage / Q000037:antagonists & inhibitors* / Q000276:immunology*; D006467:Hemophilia A / Q000097:blood / Q000150:complications / Q000276:immunology*; D006801:Humans; D008297:Male; D006255:Rhinitis, Allergic, Seasonal / Q000150:complications / Q000276:immunology / Q000628:therapy; D000069283:Rituximab; D018417:Th1 Cells / Q000276:immunology; D018418:Th2 Cells / Q000276:immunology; D014612:Vaccines / Q000008:administration & dosage* / Q000276:immunology
D000485:Allergens; D058846:Antibodies, Monoclonal, Murine-Derived; D019774:Blood Coagulation Factor Inhibitors; D014612:Vaccines; D000069283:Rituximab; D005169:Factor VIII